Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05488262
Other study ID # 2022-A00455-38
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date February 2, 2024
Est. completion date August 2, 2024

Study information

Verified date February 2024
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients hospitalized in intensive care between January 2014 and September 2021 for ketoacidosis complicated by organ failure in participating departments.


Description:

Analysis of patients with International Statistical Classification of Diseases and Related Health Problems coding compatible with inclusion - Selection of patients eligible for inclusion based on review of medical records (verification of inclusion and non-inclusion criteria) - Telephone contact and sending of the information letter on participation in the study and research of the patient's non-opposition to his participation and the processing of his data. - Collection of retrospective data - Phone call to collect prospective data


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 200
Est. completion date August 2, 2024
Est. primary completion date February 2, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Major (age = 18 years old) - Hospitalized in intensive care between January 2014 and September 2021 for ketoacidosis complicated by organ failure in the participating departments. - Diagnosis of ketoacidosis judged to be the main cause of the severity of the clinical condition. - Blood potential hydrogen < 7.15 and bicarbonates < 10mmol/L in the first 12 hours of treatment. - Presenting at least one of the 3 organ failures during hospitalization among: - Use of extra-renal purification for acute renal failure - Administration of pressor amines - Use of mechanical ventilation Exclusion Criteria: - Metabolic acidosis primarily of an origin other than ketonic - Refusal to participate or opposition to the processing of their data - Patient under guardianship or curators

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France Avicenne Bobigny
France Louis Mourier Colombes
France Bicêtre Le Kremlin-Bicêtre
France Saint-Louis Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary evaluate the incidence of mortality in intensive care units of patients hospitalized for severe diabetic ketoacidosis. Percentage of mortality in intensive care units in patients admitted for ketoacidosis complicated by organ failure. up to 6 months
See also
  Status Clinical Trial Phase
Completed NCT02077348 - Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection. N/A
Completed NCT02157155 - A Study of Intracellular Signaling in Muscle and Fat Cells During Ketosis N/A
Completed NCT05442918 - Expected Normal Ketone Values After Very Low and Bariatric Surgery
Terminated NCT01631929 - Two Bag System for Hydration in Diabetes N/A